Quality policy
“The focus of Tada Group is needs-based R&D. Our medical devices are based on research, design, development, manufacturing in accordance with Tada Group’s QMS and applicable regulatory requirements with focus on customer needs. Tada Group provides breakaway connectors to be used as value enhancing components for IV lines preventing catheter failure due to mechanical complications.”
ReLink
ReLink is a patented breakaway connector, designed to prevent mechanical complications such as dislodgement, thereby providing increased safety for patients and nurses. It comprises a weak link concept to reduce IV catheter dislodgement in combination with self-sealable valves to prevent spill of IV fluids, medicine, and blood.
Advantages for patients
-
Minimises risks of IV catheter complications such as dislodgement
-
Reduces patient injuries and risk for infections
-
Supports accurate drug delivery
Advantages for nurses
-
Reduces risk of toxic drug exposure
-
Reduces risk of blood exposure
-
Reduces unnecessary workload and unlocks valuable nursing hours
Catalogue
ReLink is a groundbreaking platform technology poised to redefine patient safety and healthcare efficiency. It sets a new standard in IV therapy—minimising medical errors, unlocking valuable nursing hours, and opening a multitude of opportunities.
First generation single-use breakaway connector promoting increased safety for patient and healthcare professionals. CE approved for gravitational IV therapy.
IV catheter accessory for animal care. Suitable for companion animals and larger animals such as foals.
Dislodgement prevention tailored for pigtail nephrostomy catheters. The self-sealing valves prevent soiling of the bed and surrounding environment upon separation of the ReLink parts.
Embracing the power of the ReLink technology
Our R&D team is working to extend the ReLink technology to cover also the following market segments.
A digital add-on to the all-mechanical core ReLink technology will facilitate moving IV therapy from the hospital to the home, which could save up to 90% of treatment costs.
A closed system connector device that eliminates leakage of toxic liquids and vapours to safekeep healthcare professionals working with hazardous drugs such as chemotherapy.
A ReLink functionalised with an antimicrobial barrier would be specially beneficial for immunocompromised patients and central line usage.
Research support
The project has received funding from the European Union's Horizon 2020 research and innovation programme under EIC Accelerator grant, Fast Track to Innovation grant and from the Eurostars-2 Joint Programme with co-funding from the European Union's Horizon 2020 research and innovation programme
Sustainability
Our innovation not only addresses healthcare and patient safety, but also the wider concerns of European and global importance as outlined in the 2030 agenda for sustainable development.
Goal 3: Good health and well-being
ReLink is a solution that disrupts the state-of-the-art of IV therapy. The elderly patients, psychiatric patients, as well as paediatric patients will particularly benefit from the improvements that ReLink offers.
Goal 6: Clean water and sanitation
ReLink aids in curbing hazardous chemical pollution, lowering medication wastage, and promoting affordable healthcare solutions, thus addressing global challenges and enhancing safety.
Goal 8: Decent work and economic growth
ReLink enhances global healthcare by saving time and costs, preventing spills, ensuring safety, and creating a positive working environment for healthcare professionals, while being adaptable for home care.
Goal 12: Responsible consumption and production
ReLink will align towards improper waste handling, not only for medicine and chemicals, but also by saving plastic waste annually in Europe and USA.